NeurAxis, Inc. announced on January 21, 2025, new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) with Molina Healthcare. This coverage extends to approximately 5.1 million members across 13 states, including initial expansion into Michigan, Illinois, New York, and Texas.
This milestone contributes to a significant increase in total insurance coverage for NeurAxis's IB-Stim device, which is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 years. The company now reports approximately 51 million lives under insurance coverage, a substantial leap from 4 million a year ago.
The expanded coverage, alongside the recently achieved CPT Category I code and the broader age range for IB-Stim, is expected to enhance patient access to the therapy. This progress is driven by the company's published research and is crucial for accelerating the adoption of IB-Stim among the estimated 600,000 individuals suffering from IBS.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.